Our Programs

Pipeline

Our development programs represent the potential to improve the well-being of people whose lives are currently limited by rare disease.

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases, with the goal of addressing the unmet medical needs of patients and physicians.

BioCryst’s core development programs include:

  • BCX7353 and additional 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema (HAE)
  • BCX9250 and BCX9499 for Fibrodysplasia Ossificans Progressiva (FOP)
  • BCX4430 (galidesivir), a broad-spectrum antiviral for hemorrhagic fevers

BioCryst’s discovery team is also designing drug candidates against additional undisclosed rare disease targets.

In December 2014, RAPIVAB® (peramivir injection) was approved by the FDA, the first FDA approval of a drug discovered by BioCryst.

For inquiries about licensing opportunities, please contact our business development group.

Program
  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved
Phase
Hereditary Angioedema (HAE)
fibrodysplasia ossificans progressiva (FOP)
Pre-clinical
Pre-clinical
other rare diseases
Second Generation Kallikrein Inhibitors
Pre-clinical
Unspecified
Pre-clinical
infectious diseases

Targeting Hereditary Angioedema (HAE)

We are working to revolutionize HAE treatment with new and novel orally-administered medicines.

See More